CStone Pharmaceuticals (HKG:2616)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 15.06B +232.4% |
| Revenue (ttm) | 299.99M -33.8% |
| Net Income | -486.30M |
| EPS | -0.35 |
| Shares Out | 1.47B |
| PE Ratio | n/a |
| Forward PE | 48.20 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,060,000 |
| Average Volume | 21,551,698 |
| Open | 10.23 |
| Previous Close | 10.23 |
| Day's Range | 9.88 - 10.32 |
| 52-Week Range | 2.30 - 13.15 |
| Beta | 0.27 |
| RSI | 75.34 |
| Earnings Date | Mar 26, 2026 |
About CStone Pharmaceuticals
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor... [Read more]
Financial Performance
In 2025, CStone Pharmaceuticals's revenue was 269.58 million, a decrease of -33.80% compared to the previous year's 407.21 million. Losses were -437.00 million, 379.1% more than in 2024.
Financial numbers in CNY Financial StatementsNews
CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0
Rapid Advancement Across Core R&D Pipeline The global, multicenter Phase I/II clinical trial of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) is actively enrolling patients in Australia and China, an...
CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
Key Highlights: Excellent Safety Profile: As of mid-March 2026, 113 heavily pretreated patients with solid tumors have been enrolled in the Phase I trial of CS2009, with a median follow-up of approxi...
CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC
Following approval by the European Commission (EC), sugemalimab has received a new indication approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for stage III non-small ce...